Since melanoma is a skin cancer and chemokines participate in its progression, utilizing previous strategy in the modulation of CXCR1/CXCR A study was developed to design a novel PSMA–PI3K small patch drug conjugate known through affecting Pi3K/AKT can further enhance its treatment. This evidence concerns the gene CXCR1 and melanoma.